News & Updates

Men with inflammatory bowel disease (IBD) have a slightly reduced fertility, and this is observed in both ulcerative colitis and Crohn’s disease, as reported in a study.

A once-weekly subcutaneous dose of the GLP-1* receptor agonist dulaglutide successfully controlled glycaemic levels in youths with type 2 diabetes (T2D) being treated with lifestyle modification with or without metformin or insulin, results of the multinational, phase III AWARD-PEDS** study showed.

Estimated pulse wave velocity (ePWV) and socioeconomic status (SES) independently contribute to a higher risk of stroke in men, and the relationship between elevated ePWV and increased stroke risk remains whether an individual has high or low SES, according to a study.

Regardless of the use of medication, levels of low-density lipoprotein cholesterol (LDL-C) appear to be appropriately managed in older type 2 diabetes mellitus (T2DM) patients, contributing to the prevention of coronary artery disease (CAD), a recent study has found.

Treatment with bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL-17A, significantly improved ASAS40* response rate in patients with either nonradiographic axial spondyloarthritis (nr-axSpA) or ankylosing spondylitis (AS**), according to two phase III studies presented at EULAR 2022.

The biologic dupilumab appears to be a hit with atopic dermatitis (AD) patients treated in the real-world setting, with patients experiencing prompt improvements in multiple aspects of disease control that persisted through 1 year, as shown in the results of the RELIEVE-AD* study.